PLYX Company Profile and Key Details

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $10.00 to $10.00. The high target offers 184.09% upside. The low target suggests 184.09% downside. The mean target is $10.00. This offers 184.09% upside.

Short-term trend indicators are mixed aligned (SMA20 -60.97%, SMA50 -60.97%, SMA200 -60.97%). The stock’s 14-day RSI is 7.92 (weak momentum), while the ATR of 4.61 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -93.48% below its high and over 44.93% above its low. Average 10-day trading volume of 300.23 thousand shares is below the 3-month average of 3.42 million, indicating normal recent market interest.

Polaryx Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.02. This means the shares are trading above this model’s fair value.

Polaryx Therapeutics, Inc. Common Stock (NASDAQ:PLYX) closed at $5.97 USD, gaining $2.45 (69.60%) from the previous close of $3.52. The stock is currently mid-range between its 52-week high and low $2.20 and $48.91. With a market capitalization of about $281.13 million, Polaryx Therapeutics, Inc. Common Stock is classified as a micro-cap and shows lower-than-market volatility (beta ~0.00). Key stats such as the average daily volume over the past year has been around 2.52 million shares, trading with heavier-than-usual volume. Headquartered in Paramus, NJ, Polaryx Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Alex Yang, the company employs approximately 11 people and listed since February 02, 2026. Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders.

Our AI price prediction model suggests that Polaryx Therapeutics, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -29.83%, with price expected at $2.47 by March 23, 2026, within a range of $1.77 to $3.21 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by June 05, 2026, with a range of $0.00 to $0.00. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by March 09, 2027, within a range of $0.00 to $0.10.

currently trading near 52-week highs band. Valuation shows Polaryx Therapeutics, Inc. Common Stock trading at a premium to the broader market with a P/E of -137.88. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $10.00, suggesting 184.09% upside. Our AI forecast model points to short-term weakness (-29.83% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Polaryx Therapeutics, Inc. Common Stock trades at a P/E ratio of -137.88, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 213.63 reflecting a rich premium to book value. The P/FCF stands at -114.66, also below market averages. Compared to sector medians, Polaryx Therapeutics, Inc. Common Stock P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.